# Arca Biopharma Probability Of Bankruptcy

ABIO | - USA Stock | ## USD 2.35 0.06 2.62% |

Arca Biopharma | Probability Of Bankruptcy |

**M**this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (19.7

**M**).

## Arca Biopharma Probability Of Bankruptcy Analysis

Arca Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years. 2019 | 2020 | 2021 | 2022 (projected) | |

Tangible Asset Value | 8.54 M | 50.43 M | 54.92 M | 59.26 M |

Market Capitalization | 9.1 M | 37.38 M | 30.98 M | 28.35 M |

Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Arca Biopharma Probability Of Bankruptcy | 4% |

Most of Arca Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arca Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Arca Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Arca Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Arca Biopharma financial health.

Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others. The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Arca Biopharma Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Arca Biopharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Arca Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arca Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arca Biopharma's interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Arca Biopharma has a Probability Of Bankruptcy of 4.0%. This is 90.76% lower than that of the Healthcare sector and 92.71% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 89.96% higher than that of the company.

## Arca Biopharma Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arca Biopharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arca Biopharma could also be used in its relative valuation, which is a method of valuing Arca Biopharma by comparing valuation metrics of similar companies.Arca Biopharma is currently under evaluation in probability of bankruptcy category among related companies.

## Arca Biopharma Main Bankruptcy Drivers

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Return on Average Assets | (1.1) | (0.83) | (0.58) | (0.32) | (0.31) | (0.34) | |

Total Liabilities | 2.09 M | 793 K | 926 K | 3.91 M | 3.88 M | 3.07 M | |

Current Liabilities | 2.07 M | 793 K | 926 K | 3.5 M | 3.5 M | 2.82 M | |

Total Assets | 12.37 M | 6.83 M | 8.54 M | 50.43 M | 54.92 M | 59.26 M | |

Current Assets | 12.3 M | 6.78 M | 8.48 M | 49.97 M | 54.42 M | 58.72 M | |

Net Cash Flow from Operations | (17.47 M) | (8.24 M) | (4.8 M) | (7.72 M) | (18.76 M) | (19.26 M) | |

Weighted Average Shares | 579.52 K | 769.39 K | 1.32 M | 4.71 M | 13.9 M | 15 M | |

Weighted Average Shares Diluted | 579.52 K | 769.39 K | 1.32 M | 4.71 M | 13.9 M | 15 M |

## Arca Biopharma Fundamentals

Return On Equity | (35.07) % | |||

Return On Asset | (20.93) % | |||

Current Valuation | (29.85 M) | |||

Shares Outstanding | 14.41 M | |||

Shares Owned by Insiders | 0.74 % | |||

Shares Owned by Institutions | 15.96 % | |||

Number of Shares Shorted | 325.24 K | |||

Price to Earning | (0.63) X | |||

Price to Book | 0.58 X | |||

Price to Sales | 2.08 X | |||

Revenue | 25.55 M | |||

Gross Profit | 28.37 M | |||

EBITDA | (18.77 M) | |||

Net Income | (18.77 M) | |||

Cash and Equivalents | 58.31 M | |||

Cash per Share | 4.05 X | |||

Total Debt | 507 K | |||

Debt to Equity | 0.009 % | |||

Current Ratio | 18.75 X | |||

Book Value Per Share | 3.93 X | |||

Cash Flow from Operations | (16.81 M) | |||

Short Ratio | 1.41 X | |||

Earnings Per Share | (1.49) X | |||

Number of Employees | 11 | |||

Beta | 2.43 | |||

Market Capitalization | 33 M | |||

Total Asset | 27.07 M | |||

Retained Earnings | (155.82 M) | |||

Working Capital | (20.73 M) | |||

Current Asset | 5.88 M | |||

Current Liabilities | 26.61 M | |||

Z Score | 32.0 |

## About Arca Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arca Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arca Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arca Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
## Be your own money manager

Our tools can tell you how much better you can do entering a position in Arca Biopharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Money Flow Index Now

## Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |

All Next | Launch Module |

## Pair Trading with Arca Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arca Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arca Biopharma will appreciate offsetting losses from the drop in the long position's value.## Arca Biopharma Pair Correlation

### Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Arca Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arca Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arca Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arca Biopharma to buy it.

The correlation of Arca Biopharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arca Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arca Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arca Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Please continue to Arca Biopharma Piotroski F Score and Arca Biopharma Altman Z Score analysis. Note that the Arca Biopharma information on this page should be used as a complementary analysis to other Arca Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

## Complementary Tools for Arca Biopharma Stock analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.

Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account | Go | |

Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets | Go | |

Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk | Go | |

Stock ScreenerFind equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | Go | |

Equity ValuationCheck real value of public entities based on technical and fundamental data | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Content SyndicationQuickly integrate customizable finance content to your own investment portal | Go | |

Piotroski F ScoreGet Piotroski F Score based on binary analysis strategy of nine different fundamentals | Go | |

CEO DirectoryScreen CEOs from public companies around the world | Go |

The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.